financial guidance
Point-of-Care Test Developer LumiraDx Goes Public on Nasdaq
LumiraDx said it has a pipeline of more than 30 assays for conditions that include infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders.
Thermo Fisher Scientific Expects 12 Percent Revenue Growth in 2022
The guidance for next year assumes, among other things, $6.0 billion in revenue from clinical research services provider PPD, which Thermo Fisher is set to acquire this year.
Quest Diagnostics Raises Full Year 2021 Guidance Due to Strong COVID-19 Molecular Test Demand
The company expects demand for molecular COVID-19 testing to remain elevated in the second half of this year.
LumiraDx, CA Healthcare Acquisition Revise Merger Terms to Lower Equity Value of Combined Company
The firms said that lowering the pro forma enterprise value of post-merger LumiraDx is expected to make the new company more attractive to investors.
SomaLogic Boosts Full-Year 2021 Revenue Guidance by 10 Percent
The company said that it expects to exceed its previous full-year 2021 guidance of $66.7 million in revenues by 10 percent or more.
Aug 17, 2021
Agilent Technologies Q3 Revenues Rise 26 Percent
Aug 9, 2021
Castle Biosciences Q2 Revenues Rise 79 Percent
Aug 9, 2021
Exagen Posts 43 Percent Increase in Q2 Revenues
Aug 6, 2021
NeoGenomics Q2 Revenues Grow 40 Percent
Aug 5, 2021
Natera Q2 Revenues Grow 64 Percent
Aug 5, 2021
Bio-Techne Q4 Revenues Jump 47 Percent
Jul 29, 2021
Qiagen Q2 Revenues Grow 28 Percent
Jul 29, 2021
CareDx Q2 Revenues up 77 Percent
Jul 28, 2021
Exact Sciences Q2 Revenues Rise 62 Percent
Jul 28, 2021